NasdaqGS - Nasdaq Real Time Price USD

Evotec SE (EVO)

3.9600

+0.3800

+(10.61%)

As of 12:48:44 PM EDT. Market Open.

Evotec SE (EVO) (Q4 2024) Earnings Call Highlights: Strong Q4 Performance and Strategic ...

Evotec SE (EVO) reports robust Q4 results with significant revenue growth and strategic advancements despite challenges in the R&D segment.

GuruFocus.com 4 days ago

EVT.DE
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering ...

ACCESS Newswire 5 days ago

EVO
+10.61%
EVOTF
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference ...

ACCESS Newswire 12 days ago

EVO
+10.61%
EVOTF
Is Evotec (EVO) the Best German Stock to Buy According to Hedge Funds?

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Evotec (NASDAQ:EVO) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published by Roland […]

Insider Monkey 19 days ago

EVT.DE
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ...

ACCESS Newswire last month

EVO
+10.61%
EVOTF
Evotec Announces Change in Management Board

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock ...

ACCESS Newswire last month

EVO
+10.61%
EVOTF
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology ...

ACCESS Newswire 2 months ago

EVO
+10.61%
EVOTF
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel ...

ACCESS Newswire 4 months ago

EVO
+10.61%
EVOTF
Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks were higher in Friday afternoon trading, with the NYSE Health Care Index and the

PREMIUM
MT Newswires 4 months ago

APLT

EVT.DE
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. Shares up.

Zacks 4 months ago

HALO

EVT.DE
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash, implying a fully diluted equity value of 2.0 billion euro. This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said. In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling cont

Benzinga 4 months ago

HALO

EVT.DE
Comment on Withdrawn Non-Binding Offer

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding ...

ACCESS Newswire 4 months ago

EVO
+10.61%
EVOTF
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German drug developer Evotec.

Investing.com 4 months ago

HALO

EVT.DE
Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec

(Reuters) -Halozyme Therapeutics has pulled its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday. Shares of Halozyme rose 4.70% to $47.80, while the U.S.-listed stock of Evotec tumbled 19.63% to $4.30. "To date, Evotec has been unwilling to engage with us to explore a potential combination, and a company spokesperson has publicly commented that its goal is to remain an independent company," said Halozyme CEO Helen Torley.

Reuters 4 months ago

HALO

EVT.DE
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.

PR Newswire 4 months ago

EVO
+10.61%
EVOTF

HALO
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

BioPharma Dive 4 months ago

HALO

EVT.DE

ARGX
Is Evotec SE (EVO) the Best German Stock to Buy Now?

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where Evotec SE (NASDAQ:EVO) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]

Insider Monkey 4 months ago

EVT.DE
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.

PR Newswire 5 months ago

HALO

EVO
+10.61%
EVOTF
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec SE (NASDAQ:EVO) to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion). The proposal represents a premium of 109% to Evotec’s undisturbed share price on October 15, 2024, the day before Triton Partners’ initial accumulation of Evotec shares. Evotec offers drug discovery and development services to several bio

Benzinga 5 months ago

EVT.DE

HALO
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

PREMIUM
MT Newswires 5 months ago

HALO

EVT.DE

Performance Overview

Return	EVO	DAX P (^GDAXI)
YTD	-8.76%	+6.95%
1-Year	-43.99%	+19.22%
3-Year	-71.83%	+50.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evotec SE (EVO)

Evotec SE (EVO) (Q4 2024) Earnings Call Highlights: Strong Q4 Performance and Strategic ...

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

Is Evotec (EVO) the Best German Stock to Buy According to Hedge Funds?

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec Announces Change in Management Board

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Sector Update: Health Care Stocks Rise in Afternoon Trading

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Comment on Withdrawn Non-Binding Offer

Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

Halozyme withdraws $2.1 billion buyout offer for German drug developer Evotec

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Is Evotec SE (EVO) the Best German Stock to Buy Now?

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Performance Overview